Antibody responses to the host-protective Taenia solium oncosphere protein TSOL18 in pigs are directed against conformational epitopes by ASSANA, E et al.
Antibody responses to the host-protective Taenia solium oncosphere
protein TSOL18 in pigs are directed against conformational epitopes
E. ASSANA,
1,2 C. G. GAUCI,
2 C. T. KYNGDON,
2 A. P. ZOLI,
3 P. DORNY,
1 S. GEERTS
1 & M. W. LIGHTOWLERS
2
1Department of Animal Health, Prince Leopold Institute of Tropical Medicine, Antwerpen, Belgium,
2Veterinary Clinical Centre,
The University of Melbourne, Werribee, Vic., Australia,
3Faculty of Agronomy and Agricultural Sciences, University of Dschang,
Dschang, Cameroon
SUMMARY
TSOL18 is a recombinant protein that has been shown in
repeated experimental trials to be capable of protecting pigs
against challenge infection with the cestode parasite Taenia
solium. Antibodies raised by the vaccine are capable of kill-
ing the parasite in an in vitro culture and it is believed that
antibody and complement-mediated killing of invading para-
sites is the major protective immune mechanism induced by
vaccination with TSOL18. Investigations were undertaken to
characterize whether the principal antibody specificities
raised by TSOL18 in pigs were against linear or conforma-
tional determinants. TSOL18 was expressed in two trun-
cated forms representing either the amino terminal portion
or the carboxy terminal portion, with the two truncations
overlapping in sequence by 25 amino acids. The original pro-
tein (designated TSOL18N
)) and the two truncations
(TSOL18N
)-1 and TSOL18N
)-2) were used in inhibition
ELISA. TSOL18N
) was shown to be capable of completely
inhibiting the binding of pig anti-TSOL18N
) antibodies to
TSOL18N
) in ELISA. However, neither TSOL18N
)-1 nor
TSOL18N
)-2, either alone or when combined together, was
capable of inhibiting any detectable amount of reactivity of
pig anti-TSOL18N
) antibodies with TSOL18N
). It is con-
cluded that the dominant antibody specificities, and probably
the host-protective specificities, of TSOL18 are conforma-
tional epitopes.
Keywords conformational epitope, cysticercosis, pig, Taenia
solium, TSOL18, vaccine
INTRODUCTION
Taenia solium is a zoonotic parasite prevalent in many
developing countries of Asia, Africa and the Americas
(1–3). The parasite lifecycle involves pigs and humans.
Transmission to pigs is through the ingestion of faeces
from a human infected with the adult T. solium tapeworm,
or items contaminated with such faeces. Control of the
disease can be achieved by improvements in sanitary con-
ditions concerning the disposal of human faeces and
through prevention of pigs gaining access to human faeces.
However, in many areas of the developing world where the
disease is prevalent, these measures are unlikely to be
implemented in the foreseeable future. Efforts have been
made to control this disease, but few countries have been
able to eradicate or reduce the infection level using
approaches such as anthelmintic treatment of humans or
pigs, restriction of roaming pigs, health education or meat
inspection. Failure to control T. solium cysticercosis using
these approaches in the last decades has indicated that
eradication of this zoonosis will be difficult to achieve (4).
Vaccines have been proposed as a new approach to
control pig cysticercosis and interrupt the life cycle of T. so-
lium (5). Several candidate vaccines are now available (6–8).
Antigens derived from the oncosphere lifecycle stage have
been the most effective in inducing protection against exper-
imental challenge infection with taeniid cestode parasites
(9). Development of a vaccine against Taenia ovis infection
in sheep (10) provided a model for identification of homolo-
gous antigens in related parasites (11). Subsequently, a num-
ber of effective vaccines have been developed based on
oncosphere proteins expressed in Escherichia coli (9). Adop-
tion of a similar approach for T. solium led to the discovery
of the protein TSOL18, which has been found to induce
between 99Æ3 and 100% protection in five experimental
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  2010 Blackwell Publishing Ltd 399challenge trials carried out in four different countries
(12,13, reviewed in Ref. 9). Investigations into the molecular
aspects of gene structure and the translated protein
sequences show that the various host-protective oncosphere
antigens from different taeniid cestode species show com-
mon features in the structure of the proteins. These include
a predicted secretory signal sequence and one or two copies
of a fibronectin type III domain (FNIII; 13,14).
A principal host-protective immune mechanism induced
by oncosphere antigens against taeniid cestode infections is
antibody and complement-mediated killing of early stages
in the development of the parasite in the intermediate host
(9). Little is known about the nature of the host-protective
epitopes associated with the various oncosphere proteins
that are under development as practical vaccines. Knowl-
edge of the nature of antigenic sites recognized by antibody
is an important component in understanding the character-
istics of avaccine antigen and the development of associated
immunological assays (15). Efforts to identify protective epi-
topes have, to date, not been successful (16–18). The antigen
about which most information is available is the EG95 pro-
tein from the related parasite Echinococcus granulosus.
Strong evidence has been obtained that the host-protective
epitopes associated with this antigen are principally, or
entirely, associated with the tertiary conformation of the
protein and not associated with linear epitopes (17).
TSOL18 is undergoing further development in anticipa-
tion of its application in the control of transmission of
T. solium through pigs. At present the vaccine comprises a
purified recombinant protein. While this source of vaccine
antigen may be effective, production of recombinant pro-
teins is relatively expensive and an attractive alternative
would be the use of a defined protective epitope produced
synthetically. The use of such a precise epitope which corre-
sponds to the specificity of a known protective antibody
could induce the generation of antibodies similar to those
elicited by the vaccine (19). There are many similarities
between TSOL18 and the EG95 protein, including the
presence of a secretory signal sequence followed by a single
FNIII domain. In the experiments described in this study
we use sera from pigs known to be protected against T. so-
lium infection in in vitro assays with the TSOL18 protein
and with truncated recombinant forms of TSOL18 to
determine whether the host-protective anti-TSOL18 anti-
bodies are associated with conformational determinants.
METHODS
Preparation of TSOL18
The TSOL18 antigen used in these experiments was identi-
cal to the vaccine protein used in the successful vaccine
trials described by Flisser et al. (7) and Gonzalez et al.
(12) being an N-terminal truncation of the full length
TSOL18 protein from which the 18 amino acid secretory
signal sequence had been deleted. The nomenclature used
here for this protein is TSOL18N
). The protein was
expressed as a C-terminal fusion to glutathione S-transfer-
ase (TSOL18N
)-GST; 12). TSOL18N
) was also expressed
as a maltose binding protein (MBP) fusion by cloning and
expressing TSOL18N
) cDNA into pMAL using standard
procedures (20). Soluble TSOL18N
)-GST or TSOL18N
)-
MBP were affinity purified from E. coli proteins using
glutathione-sepharose (Amersham Bioscience, Uppsala,
Sweden) or maltose beads (Biolabs, New England, UK)
for the GST and MBP fusion proteins respectively. Control
proteins were prepared from E. coli transformed with the
pGEX or pMAL vectors according to the manufacturers’
instructions.
Preparation of truncated TSOL18N
)
Two truncated TSOL18N
) proteins (TSOL18N
)-1, TSOL
18N
)-2) were expressed in E. coli as GST fusion proteins.
PCR products were amplified from the TSOL18N
) cDNA
template so as to express the truncated proteins shown in
Figure 1a. Amplification of TSOL18N
) cDNA fragments
was undertaken using the following primer pairs:
TSOL18-1, 5¢GAA TTC GAC CGA ACA TTC GGC
GAC G 3¢,5 ¢CTC GAG TCA CTT CAA GTC TCT CTG
ATG AC; TSOL18-2, 5¢ GAA TTC GCA ATA CAC
CCA TAC AAG ATC TG 3¢,5 ¢ CTC GAG TCA GCA
TTG CCT GCT CCG CGC 3¢.
PCR was performed in a total volume of 50 lL contain-
ing 0Æ3m M dNTP, 1 mM MgSO4,1 Æ25 Units Pfx DNA poly-
merase (Invitrogen, Carlsbad, CA, USA), 1 · Pfx reaction
buffer (Invitrogen), primers 20 ng each and 0Æ1 ng pGEX-
1TEX-TSOL18N
) template. Amplification was carried out
in Perkin Elmer GeneAmp PCR Reactor 9600 (Perkin
Elmer, Waltham, MA, USA) for 30 cycles consisting of
94 C for 30 s, 55 C for 30 s, 68 C for 1 min. Reaction prod-
ucts were ethanol precipitated, restriction digested with
EcoRI and XhoI, separated using TAE-agarose gel electro-
phoresis and visualized using SYBR Green (Invitrogen).
Stained bands were excised and purified using a Qiagen
Minelute kit. EcoRI and XhoI digested TSOL18N
)-1-DNA
and TSOL18N
)-2-DNA were ligated to previously EcoRI
and XhoI digested pGEX-1TEX and transformed into
E. coli BL21 DE3 using electroporation. DNA sequence of
the clones was confirmed using dideoxy chain termination
method using the Applied Biosystems ABI PRISM
TM
sequencing system and BIG DYE V3.1 terminator cycle
sequencing kit. Sequencing results were analysed using DS
Gene software (ACCELRYS, San Diego, CA, USA).
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)-1 comprised the amino-terminal 71 amino
acids of TSOL18N
) (Figure 1a) while TSOL18N
)-2 con-
sisted of the carboxy-terminal 66 amino acids of
TSOL18N
) with the two truncated proteins overlapping
each other by 25 amino acids. All the steps of production
and purification of truncated antigens fused with glutathi-
one S-transferase were identical to those used for the full
length TSOL18N
)-GST protein.
Serum samples
Sera were obtained from two pigs immunized with
TSOL18N
)-GST (whole proteins) and two pigs immunized
with the combined two fragments of TSOL18N
). The
immunizations consisted of 200 lg of soluble antigens plus
1 mg of the adjuvant Quil-A (Superfos Biosector, Vedbaek,
Denmark) given a month apart. Sera were collected at
2 weeks post second immunization. In addition, sera from
two Cameroonian pigs collected 4 weeks after experimental
infection with T. solium eggs (21), were obtained from the
bank sera of the Animal Health Department of the Institute
of Tropical Medicine, Belgium.
Oncosphere antigen
Enzyme-linked immunosorbent assays
TSOL18N
)-specific antibody titres were determined using
enzyme-linked immunosorbent assay (ELISA) using
TSOL18N
)-MBP as antigen (to differentiate anti-
TSOL18N
) antibodies from those raised against the GST
component of TSOL18N
)-GST). Optimal concentrations
of antigen and enzyme conjugated secondary antibody
were determined in checker board titrations. ELISA plates
(Nunc , Polysorb, Roskilde, Denmark) were coated over-
night at 4 C with TSOL18N
)-MBP (5 lg⁄mL) in carbon-
ate buffer (0Æ06 M,p H9 Æ6, 100 lL⁄well). The plates were
washed once with phosphate-buffered saline containing
0Æ05% Tween 20 (PBST) and blocked by incubation with
150 lL per well of 2% new born calf serum in phosphate-
buffered saline-0Æ05% Tween 20 (NBCS-PBST) for 1 h at
37 C. Plates were emptied and 100 lL of test serum
samples serially diluted in NBCS-PBST were added and
incubated at 37 C for 1 h after which the plates were
washed five times with PBST and incubated with 100 lL
per well of rabbit anti-porcine IgG conjugated to horserad-
ish peroxidise (HRP) (Sigma-Aldrich Corp, St Louis, MO
USA) diluted at 1⁄20 000 in NBCS-PBST at 37 C for 1 h.
Subsequently the plates were washed as above and chromo-
gen⁄substrate solution (Ortophenylene diamine and H2O2)
was added (100 lL⁄well) and incubated at 37 Cf o r
15 min. The reaction was stopped by addition of 50 lLo f
4N H2SO4 to each well. Optical densities (OD) were mea-
sured at 492 nm using a microplate reader (Multiscan EX;
Thermo Scientific, Waltham, MA, USA). Titres were cal-
culated as the dilution at which the sera had an OD of 1Æ0.
Inhibition ELISA
Inhibition ELISAwere performed using two methodologies.
Tests using serially diluted antigen and constant amount of
antibodies were undertaken as follows. ELISA plates
(Microlon 655061; Greiner Bio-One, Longwood, FL,
USA) were coated and blocked in the manner described
above. Antigens TSOL18N
)-GST, TSOL18N
)-MBP,
(a)
97-
66-
45-
30-
20.1-
123 M (b)
Figure 1 Amino acid sequence of T. solium TSOL18N
) and truncated proteins TSOL18N
)-1 and TSOL18N
)-2 (a) and the appearance of
the proteins as GST fusions in SDS PAGE (b). M, molecular weight markers, 1 TSOL18N
)-1, 2 TSOL18N
)-2, 3 TSOL18N
).
Volume 32, Number 6, June 2010 Epitope characteristics of Taenia solium TSOL18
  2010 Blackwell Publishing Ltd, Parasite Immunology, 32, 399–405 401TSOL18N
)-1 or TSOL18N
)-2 were serially diluted in
PBST to obtain 11 concentrations from 3Æ21 pmol⁄mL to
3290Æ55 pmol⁄mL. In total 150 lL of antisera (1⁄100 in
PBST-1% sodium caseinate-20% E. coli lysate) was added
to 150 lL of each serial dilution of antigen and incubated
at 37 C for 2 h. A total of 100 lL of each of the inhibition
mixtures was added to empty wells of an ELISA plate that
had previously been coated with antigen (as for standard
ELISA) and subsequently incubated at 37 C for 1 h. Plates
were washed five times with PBST, incubated with 100 lL
per well of goat anti-porcine IgG conjugated to horseradish
peroxidise (HRP) (Serotec, Oxford, UK), diluted at 1⁄5000
in 1% sodium caseinate-phosphate-buffered saline-0Æ05%
Tween20 (SC-PBST) and incubated at 37 C for 1 h. The
plates were washed again and TMB chromogen⁄substrate
solution in phosphate⁄citrate buffer (0Æ2 M dibasic sodium
phosphate, 0Æ1 M citric acid, pH 5; 1 mM 3,3¢5,5¢ tetrameth-
ylbenzidine; 3Æ6 · 10
)2%o fH 2O2) was added (100 lL⁄well)
and incubated at 37 C for 25 min. The reaction was stopped
by adding 50 lLo f2M H2SO4 to each well. Optical densi-
ties (OD) were measured at 450 nm using a microplate
reader (Dynex Technologie Ltd, Worthing, UK).
Inhibition ELISA using a constant amount of antigen
and serially diluted antiserum were undertaken using simi-
lar procedures to those described above but a constant
amount (10 lg) of the TSOL18 antigens was added to a
serial dilution of antiserum.
RESULTS
TSOL18N
)-1-GST and TSOL18N
)-2-GST were expressed
in E. coli as soluble fusion proteins that were successfully
purified on glutathione agarose and migrated according to
their predicted sizes in SDS PAGE (Figure 1b).
Antisera raised against TSOL18N
)-GST, TSOL18N
)-
1-GST and TSOL18N
)-2-GST were found to have detect-
able levels of specific antibody in ELISA (Figure 2). The
level of reactivity measured in ELISA using TSOL18N
)-
MBP as antigen was greater in animals immunized with
TSOL18N
) than it was with sera from animals vaccinated
with the two truncated proteins (Figure 2).
Both TSOL18N
)-GST and TSOL18N
)-MBP were
potent inhibitors of pig specific antibody reactivity in
ELISA (Figures 3 and 5) irrespective of whether the assays
were performed using a constant concentration of antisera
and a varying amount of inhibitor protein (Figure 3) or
where differing amounts of anti-TSOL18N
)-GST specific
antibody was exposed to 10 lg of inhibitor protein (Fig-
ure 5). However, the proteins TSOL18N
)-1-GST and
TSOL18N
)-2-GST were unable to inhibit any detectable
level of reactivity of anti-TSOL18N
) antibodies binding to
the TSOL18N
) protein (Figures 4 and 5).
DISCUSSION
The TSOL18N
) protein was an effective inhibitor of anti-
TSOL18N
) antibody reactivity in inhibition ELISA.
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Figure 2 Antibody titres in pigs 2 weeks after a second
immunization with either TSOL18N
)-GST, a combination of
TSOL18N
)-1-GST plus TSOL18N
)-2-GST or 4 weeks post
infection with T. solium eggs. Panel headings indicate the antigen
used to raise antisera while the y-axis legends indicate the antigens
used in ELISA. Top panel shows reactivity in ELISA (€standard
deviation) with the homologous antigens (TSOL18N
)-GST,
TSOL18N
)-1-GST and TSOL18N
)-2-GST). Centre panel: specific
reactivity to the TSOL18N
)-encoded portions of the proteins
measured using the associated MBP fusion proteins as antigen, or
oncospheres, in ELISA respectively. Bottom panel: reactivity of
T. solium infected pigs (exposed to the TSOL18 native protein)
reacted against TSOL18N
) MBP fusion proteins in ELISA.
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) completely inhibited reactivity at concentra-
tions above approximately 1000 pmol⁄mL of inhibitor
antigen under the conditions of ELISA used in this study
(Figure 3). In contrast, the TSOL18 truncations
TSOL18N
)-1 and TSOL18N
)-2 did not inhibit reactivity
between anti-TSOL18N
) antibody and the homologous
antigen.
The amino acid sequences of TSOL18N
)-1-GST and
TSOL18N
)-2 overlapped in the central region of the
TSOL18N
) protein by 25 amino acids (Figure 1).
TSOL18N
)-1 comprised the 71 amino acid amino-termi-
nal portion of TSOL18N
) while TSOL18N
)-2 comprised
the 66 amino acid carboxy-terminal portion of
TSOL18N
). Antisera raised in pigs to TSOL18N
) are
known to have some level of antibodies specific for linear
determinants of the TSOL18N
) protein (18). It could be
expected that these linear epitopes of TSOL18N
) would
be present on the TSOL18N
)-1 and TSOL18N
)-2 pro-
teins. The data presented in this study would suggest that
the great majority of the specific antibodies induced in
pigs following immunization with TSOL18N
) are directed
against conformational determinants rather than linear
determinants, and that these conformational determinants
are not presented by fragments of TSOL18N
) representing
either the amino two-thirds of the protein or the carboxy
two-thirds.
Similar data were obtained by Woollard et al. (17) when
examining the nature of the antigenic epitopes of the pro-
tective oncosphere antigen EG95 of E. granulosus. In this
case, three overlapping proteins were examined, represent-
ing the amino terminal, central and carboxy terminal por-
tions of EG95. None of these proteins, either alone or as
a combination, was able to inhibit binding to EG95 in
ELISA of the host-protective antibodies in the sera of
sheep vaccinated against EG95. Vaccination of sheep with
the three overlapping proteins, representing the entire
EG95 amino acid sequence, failed to induce protection
against a challenge infection with E. granulosus whereas
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Figure 3 Inhibition ELISA where serial dilutions of
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)-MBP or MBP proteins were used
to inhibit the binding of pig anti-TSOL18N
)-GST antisera
reacting against TSOL18N
)-MBP as antigen. Serial dilutions of
inhibitory proteins were from 3Æ21 pmol⁄mL to 3290Æ55
pmol⁄mL. Both TSOL18N
)-GST, TSOL18N
)-MBP were
effective inhibitors in the assay whereas the control protein
(MBP) caused no inhibition.
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Figure 5 Inhibition ELISA where the inhibiting protein was kept
at a constant concentration and exposed to serially diluted
antisera prior to reaction in ELISA with TSOL18N
)-MBP as
antigen. TSOL18N
)-GST was an effective inhibitor of
anti-TSOL18N
)-1-GST antibody reactivity whereas neither
TSOL18N
)-1-GST nor TSOL18N
)-2-GST either singly or
together were able to induce any detectable level of inhibition.
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between pig anti-TSOL18N
)-GST and TSOL18N
).
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near total protection (17). The conclusion drawn for EG95
was that most of the host-protective antibodies raised fol-
lowing EG95 vaccination were against conformational
rather than linear determinants. EG95 and TSOL18 are
both host-protective oncosphere antigens of taeniid ces-
tode parasites, both contain a single FNIII domain and
both appear to have the host-protective epitopes associ-
ated with conformational epitopes.
Infection with taeniid cestodes induces concomitant
immunity, that is immunity against re-infection with the
same species of parasite while those parasites establishing
during the initial infection are unaffected (22). Much evi-
dence exists to indicate that a major protective mecha-
nism, if not the only protective mechanism, induced by an
initial infection or using vaccination with oncosphere anti-
gens is antibody and complement-mediated attack on the
parasite during or immediately after the oncosphere
invades the host tissues (reviewed in Ref. 9,22). Specific
antibodies in the sera of pigs vaccinated with TSOL18N
)
(23) or sheep vaccinated with EG95 (17) are able to kill
T. solium or E. granulosus oncospheres respectively, in an
in vitro culture. There are no published data concerning
the colostral transfer of immunity induced by recombinant
oncosphere antigens, however, either vaccination with
native oncosphere antigens or an initial infection with a
taeniid cestode parasite induces antibodies that are capa-
ble of transferring complete protection against infection in
na ve recipients (reviewed in Ref. 9,22). The data concern-
ing the nature of the major antibody specificities induced
in pigs by TSOL18N
) or in sheep induced by EG95 sug-
gests that the major protective epitopes of the proteins are
conformational.
Options for the development of a synthetic peptide
based vaccine are limited where the protective epitope(s)
are conformational. Phage display mimotope technology
has been applied to the characterisation of epitopes of
conformational epitopes of EG95 (24,25). One mimotope
was identified which was capable of affinity purifying pro-
tective antibody specificities, however, this represented a
minor component of the protective antibody produced by
the EG95 vaccine (25). An alternative technology that
may be applied to the further characterization of the anti-
genic epitopes on TSOL18N
) is the use of monoclonal
antibodies. Preliminary investigations (E. Assana, unpub-
lished data) have shown that mice raise antibodies against
TSOL18N
) have similar characteristics to pig antibodies
against TSOL18N
). TSOL18N
) protein was able to fully
inhibit the binding of mouse anti-TSOL18N
) antibodies
whereas TSOL18N
)-1 and TSOL18N
)-2 failed to inhibit
any reactivity of the mouse antisera against TSOL18N
)
and the homologous antigen in ELISA. These findings
suggest that the major antibody specificities raised in mice
against TSOL18N
) may be similar to those raised in vac-
cinated pigs and hence monoclonal antibody technology
may provide a suitable method to further characterize the
conformational epitopes of TSOL18N
).
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